Lin Kun-Ju, Huang Shao-Yi, Huang Kuo-Lun, Huang Chin-Chang, Hsiao Ing-Tsung
Department of Nuclear Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Department of Medical Imaging and Radiological Sciences and Healthy Aging Research Center, Chang Gung University, No. 259, Wen-Hua 1St Road, Guishan Dist., Taoyuan City, 333, Taiwan.
EJNMMI Radiopharm Chem. 2024 Apr 2;9(1):27. doi: 10.1186/s41181-024-00259-x.
Tau pathology plays a crucial role in neurodegeneration diseases including Alzheimer's disease (AD) and non-AD diseases such as progressive supranuclear palsy. Tau positron emission tomography (PET) is an in-vivo and non-invasive medical imaging technique for detecting and visualizing tau deposition within a human brain. In this work, we aim to investigate the biodistribution of the dosimetry in the whole body and various organs for the [F]Florzolotau tau-PET tracer. A total of 12 healthy controls (HCs) were enrolled at Chang Gung Memorial Hospital. All subjects were injected with approximately 379.03 ± 7.03 MBq of [F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject. For image processing, the VOI for each organ was delineated manually by using the PMOD 3.7 software. Then, the time-activity curve of each organ was acquired by optimally fitting an exponential uptake and clearance model using the least squares method implemented in OLINDA/EXM 2.1 software. The absorbed dose for each target organ and the effective dose were finally calculated.
From the biodistribution results, the elimination of [F]Florzolotau is observed mainly from the liver to the intestine and partially through the kidneys. The highest organ-absorbed dose occurred in the right colon wall (255.83 μSv/MBq), and then in the small intestine (218.67 μSv/MBq), gallbladder wall (151.42 μSv/MBq), left colon wall (93.31 μSv/MBq), and liver (84.15 μSv/MBq). Based on the ICRP103, the final computed effective dose was 34.9 μSv/MBq with CV of 10.07%.
The biodistribution study of [F]Florzolotau demonstrated that the excretion of [F]Florzolotau are mainly through the hepatobiliary and gastrointestinal pathways. Therefore, a routine injection of 370 MBq or 185 MBq of [F]Florzolotau leads to an estimated effective dose of 12.92 or 6.46 mSv, and as a result, the radiation exposure to the whole-body and each organ remains within acceptable limits and adheres to established constraints.
Retrospectively Registered at Clinicaltrials.gov (NCT03625128) on 12 July, 2018, https://clinicaltrials.gov/study/NCT03625128 .
Tau蛋白病变在包括阿尔茨海默病（AD）在内的神经退行性疾病以及诸如进行性核上性麻痹等非AD疾病中起着关键作用。Tau正电子发射断层扫描（PET）是一种用于检测和可视化人脑中Tau蛋白沉积的体内非侵入性医学成像技术。在本研究中，我们旨在研究[F]Florzolotau Tau-PET示踪剂在全身和各个器官中的剂量学生物分布。长庚纪念医院共招募了12名健康对照者（HCs）。所有受试者均静脉注射约379.03±7.03 MBq的[F]Florzolotau，并对每位受试者进行全身PET/CT扫描。对于图像处理，使用PMOD 3.7软件手动勾勒出每个器官的感兴趣区（VOI）。然后，通过使用OLINDA/EXM 2.1软件中实现的最小二乘法对指数摄取和清除模型进行最佳拟合，获取每个器官的时间-活度曲线。最终计算出每个靶器官的吸收剂量和有效剂量。
从生物分布结果来看，观察到[F]Florzolotau主要从肝脏排泄至肠道，部分通过肾脏排泄。器官吸收剂量最高的是右结肠壁（255.83 μSv/MBq），其次是小肠（218.67 μSv/MBq）、胆囊壁（151.42 μSv/MBq）、左结肠壁（93.31 μSv/MBq）和肝脏（84.15 μSv/MBq）。根据国际辐射防护委员会（ICRP）第103号出版物，最终计算出的有效剂量为34.9 μSv/MBq，变异系数为10.07%。
[F]Florzolotau的生物分布研究表明，[F]Florzolotau主要通过肝胆和胃肠道途径排泄。因此，常规注射370 MBq或185 MBq的[F]Florzolotau导致的估计有效剂量分别为12.92或6.46 mSv，因此，全身和每个器官的辐射暴露仍在可接受范围内，并符合既定的限制标准。
于2018年7月12日在Clinicaltrials.gov（NCT03625128）进行回顾性注册，https://clinicaltrials.gov/study/NCT03625128 。
Zotero 插件
